Denim Deal France sets stage for sustainable change in textile industry
This planned expansion of the initiative follows its successful implementation and achievements in the Netherlands. The Denim Deal took shape when 30 brands and industry organisations collaborated with Amsterdam's municipal government and the Dutch Ministry of Infrastructure and Water Management to make denim textile chain more sustainable.
The collaboration culminated in a formal agreement in 2020. The initiative's objectives include increasing the use of post-consumer recycled cotton, enhancing traceability, and encouraging sustainable production methods.
The Netherlands Embassy in Paris will host the inaugural event for Denim Deal France on 27 March 2025.
This event represents a significant opportunity to engage entities such as brands, sorting and collection agencies, recycling firms, weaving companies, and other critical components of the supply chain.
The launch event of Denim Deal France will focus on several key points including:
- The ambitions and commitments underlying the Denim Deal
- The advantages of joining the initiative and the prerequisites for participation
- Testimonials from participants in the Dutch Denim Deal
- Discussions with industry experts and leading figures
Denim, an enduring representation of fashion, now faces a significant challenge: minimising its environmental footprint and fully embracing a circular model.
The Denim Deal is committed to establishing a genuinely circular supply chain both within Europe and globally. It aims to produce over one billion jeans under this model by 2030.
To reach this milestone, the programme focuses on tangible commitments such as encouraging the integration of recycled cotton in new jeans manufacturing and enhancing product lifecycle traceability, minimising denim's environmental impact throughout its production process
It also seeks to prolong product lifespan to foster sustainable fashion.
Entities participating in the Denim Deal will have access to expert guidance on textile recycling, traceability, eco-design and to exclusive materials, webinars, and best practices.
They will also benefit from a network of dedicated members for sharing opportunities and innovations.
In addition, participants will gain from heightened visibility among consumers and business partners as well as a proactive stance on regulatory developments through collective strength.
"Denim Deal France sets stage for sustainable change in textile industry" was originally created and published by Just Style, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Peymo launches AI-driven multi-hybrid banking platform
UK-based fintech innovator Peymo has launched what it claims to be the world's first AI-powered digital banking platform. The multi-hybrid bank is a digital finance platform integrates traditional fiat banking, cryptocurrency wallets, tokenised assets, and embedded finance into a unified system, aiming to streamline the financial management process for users and enterprises. The platform's infrastructure is based on a proprietary modular architecture, which enables users to manage a variety of financial instruments including GBP, EUR, crypto assets, and branded debit cards in a single interface. Furthermore, the system offers APIs that allow businesses to integrate banking functions into their existing operations. Peymo platform features AI-driven voice-first interface, which supports listening, instant intent recognition, and multimodal confirmations to facilitate secure, hands-free banking transactions. The platform employs five specialised AI agents that are responsible for monitoring user behaviour, analysing market activity, optimising payment processes, and safeguarding assets in real time. Additionally, Peymo has incorporated a referral engine that can identify potential new users within a network, send out personalised invitations via communication platforms. It provides instant onboarding using AI and transaction monitoring for expedited clearance, and real-time deposits, with AI also improving of the system's code. The AI technology also aids users in navigating their financial portfolios, which may include a mix of cryptocurrencies, fiat currencies, gold, and tokenised assets. The platform offers a range of features including tokenised payments for instant remittance, multi-currency IBANs for international transactions, a built-in crypto wallet and exchange, and the ability to make contactless crypto payments at physical retail locations. Peymo founder Tomas Bartos said: "We make complex finance invisible. By fusing AI, fiat, crypto and embedded finance into a single stack, we're delivering the next generation of banking — and it's ready today." The core banking system underpinning Peymo's platform has been operational since 2012 and the company is currently seeking to raise €5m in funding and has active letters of intent from potential partners and clients across Africa, Australia, and Europe. "Peymo launches AI-driven multi-hybrid banking platform " was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
